Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

“…When calculated from our previous data (49), the predicted change in the basal metabolic rate due to changes in fasting glucose and body weight in the present study corresponds to 6.3 Ϯ 19 J/kg FFM per (49)]. Weight gain was due to a roughly similar increase in FFM and fat mass, in keeping the data showing improved glycemia to increase predominantly FFM (10) and PPAR␥ agonists mainly fat mass (50). Adverse effects of thiazolidinediones include fluid retention and the risk of heart failure (30,31).…”

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

“…Thiazolidinediones promote pre-adipocyte differentiation into small, insulin-sensitive adipocytes and induce weight gain attributable to an increase in adipose tissue mass through a redistribution of fat from ectopic sites, such as the liver and muscle, to the more physiological reservoir, the peripheral subcutaneous adipose tissue [206,212]. Recent data suggest that a plateau phenomenon in the improvement in liver steatosis and inflammation probably occurs under PPAR-c agonists, once the individual subcutaneous adipose tissue expandability reaches its storage capacity [213,214].…”

Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis

“…In clinical trials, both first-and secondgeneration thiazolidinediones were reported to decrease aminotransferase levels and improve histopathological disease stages (Reynaert et al, 2005, Promrat et al, 2004Balas et al, 2007). In particular, second-generation thiazolidinediones pioglitazone and rosiglitazone achieved promising results in clinical trials (McCul-338 ANDERSON AND BORLAK lough, 2006b;Angelico et al, 2007).…”